1. Home
  2. BEAM vs BTDR Comparison

BEAM vs BTDR Comparison

Compare BEAM & BTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$24.53

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

BTDR

Bitdeer Technologies Group

HOLD

Current Price

$9.36

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
BTDR
Founded
2017
2021
Country
United States
Singapore
Employees
N/A
246
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.3B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BEAM
BTDR
Price
$24.53
$9.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
10
Target Price
$52.21
$25.10
AVG Volume (30 Days)
1.8M
6.7M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$72.51
Revenue Next Year
$39.64
$40.84
P/E Ratio
N/A
N/A
Revenue Growth
33.33
N/A
52 Week Low
$13.53
$6.84
52 Week High
$36.44
$27.80

Technical Indicators

Market Signals
Indicator
BEAM
BTDR
Relative Strength Index (RSI) 46.20 55.18
Support Level $23.42 $7.30
Resistance Level $25.69 $9.60
Average True Range (ATR) 1.32 0.76
MACD 0.04 0.23
Stochastic Oscillator 59.52 85.14

Price Performance

Historical Comparison
BEAM
BTDR

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

Share on Social Networks: